Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman, MD, discusses findings from an ongoing phase Ib trial.
Recent Articles
Analysis of COVID-19 Clinical Trials Reveals Disorganization and Wasted Resources
An analysis cosponsored by STAT and AppliedXL, a Newlab Venture Studio company, found that clinical trials for treatments and preventative strategies for COVID-19 were...
New FDA Platform Criticized for Lack of Demographic Information
The new FDA platform Project Patient Voice, is a public database of patient-reported outcomes for clinical trials of cancer treatments intended to give patients...
Congress Seeks Formal Investigation Into Foreign Investment in US Pharmaceutical Industry
On June 30, Senators Elizabeth Warren (D-MA) and Marco Rubio (R-FL) introduced the U.S. Pharmaceutical Supply Chain Review Act, calling for a formal investigation...
FDA Approves New HIV Treatment for Patients With Restricted Options
The FDA has approved fostemsavir for adult patients with HIV who have tried multiple medications and whose HIV infection cannot be successfully treated with...
White House Further Suspends Work Visas, Affecting Science and Tech
The White House has announced the restriction of several categories of work visas for non-American citizens, in response to high unemployment levels following the...
Current Issue
July 2020 Volume 6 Issue 8
This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.
